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Background/aim: Renal oxidative stress occurs in ureteral obstructions. The purpose of this study was to investigate the effect of the
antioxidant and antiischemic agent trimetazidine (TMZ) on oxidative stress following ureteral obstruction.
Materials and methods: Ten groups were established. Sham groups were checked as controls after 1 and 3 weeks. The other 8 groups had
partial or complete ureteral obstruction while receiving or not receiving trimetazidine (TMZ) at 5 mg/kg daily and were evaluated after
either 1 week or 3 weeks. Creatinine and cystatin C measurements were performed in the serum. Malondialdehyde, myeloperoxidase,
catalase, and glutathione peroxidase activity were measured in renal tissue and serum.
Results: In the 1-week groups, tissue malondialdehyde, serum myeloperoxidase, and glutathione peroxidase activity increased
significantly with obstruction and TMZ use compared to the control group (P < 0.005). In the 3-week TMZ group, cystatin C, tissue
malondialdehyde, serum and tissue myeloperoxidase, and tissue glutathione peroxidase differed significantly (P < 0.05). There was
no significant difference in all parameters after 3 weeks of partial obstruction (P > 0.05), with only serum malondialdehyde being
significantly elevated (P < 0.05).
Conclusion: TMZ did not exhibit a renal oxidative stress-lowering effect in obstruction. It causes mild impairment of renal functions
in obstruction. Patients using TMZ must be closely monitored in terms of kidney function in the event of any ureteral obstruction.
Key words: Ureteral obstruction, renal oxidative stress, trimetazidine, renal function

1. Introduction
Obstructive uropathy results from the blockage of urinary
flow at any point in the urinary system. If the obstruction is
not relieved in time, it leads to loss of kidney function. The
most widespread cause of unilateral ureteral obstruction
(UUO) in adult humans is sudden blockage leading
to acute obstruction in a ureter. It generally appears
with ureteral stones. An obstruction-related increase in
retrograde hydrostatic pressure triggers tubular cell death
due to apoptosis and necrosis, interstitial inflammation,
decreased capillary numbers, and progressive fibrosis (1).
Oxidative stress causes injury and functional losses
in many tissues, including the kidney. Clinical and
experimental studies have shown that oxidative stress
causes glomerular, tubulointerstitial, and endothelial
changes in the kidneys and mediates the development
of several kidney diseases, such as acute kidney failure,
* Correspondence: semana52@gmail.com
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rhabdomyolysis, obstructive nephropathy, glomerular
injury, and chronic kidney failure (2).
Reactive oxygen species (ROS) are highly reactive
molecules derived from the mitochondrial electron transport
chain (3). Overproduction of ROS and/or insufficiency in the
antioxidant mechanism leads to compromise of the oxidant/
antioxidant balance and thus to oxidative stress (4–6). The
most important ROS include superoxide (O2–), hydroxyl
(OH), hydrogen peroxide, singlet oxygen, and nitric oxygen
radicals (6). Since reactive oxygen products have a rather
unstable structure due to their unpaired electron, they can
damage these structures by reacting with all elements in the
environment in order to achieve stability (3–6). Excessive ROS
formation in the body can lead to changes in the structure of
DNA, resulting in activation of transcription factors induced
by various stresses, production of pro- and antiinflammatory
cytokines, and modification of lipids (4).
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Protection of the cell against free oxygen species
occurs by means of enzymatic systems such as superoxide
dismutase (SOD), glutathione peroxidase (GPx), catalase
(CAT), thioredoxin, peroxiredoxin, and glutathione
transferase (GST) and of nonenzymatic systems such as
vitamins E and C, and glutathione (GSH). The activity
of antioxidant enzymes such as SOD, CAT, and GPx is of
considerable importance in protecting against oxidative
stress injury (3,4,6). In addition to an increase in ROS
in kidneys developing obstruction in an UUO model,
significant decreases also occur in the activity of the
important antioxidants SOD, CAT, and GPx. This decrease
in antioxidant defense contributes to the development of
oxidative stress (7–9).
Trimetazidine (TMZ) [1–(2,3,4–trimethoxybenzyl)
piperazine dihydrochloride] is an antianginal, antiischemic
drug (10). It inhibits the beta-oxidation pathway of fatty
acid metabolism (10,11), prevents overproduction of free
radicals (11), and protects cellular integrity by eliminating
ROS (12). Clinically, TMZ is used in heart disorders,
cerebral ischemia, and vertigo.
Although many studies support the protective effect
of TMZ on the heart, there is a lack of data about the
effects of this pharmaceutical on the kidney. This study
investigated the potential protective effect of TMZ on
increased oxidative stress in the kidney caused by partial
and complete UUO.
2. Materials and methods
Approval for this study, performed at the Ondokuz
Mayıs University Experimental Animals Practice and
Research Center, Turkey, was granted by the Animal
Experiments Local Ethical Committee (B.30.2.O
DM.0.20.09.00-050.04-91). Sixty-eight male, adult (2.5–3
months old), albino Sprague Dawley rats were used,
divided into 10 groups (see Table 1 for definitions of
groups G1–G10).
2.1. Surgical procedures
Laparotomy was performed under general anesthesia
(ketamine, 50 mg/kg, intramuscular), and the left ureter
was isolated. The incisions in groups G1 and G2 were
closed without narrowing being performed. An Angiocath
catheter (24 G) was placed in the ureteric lumen in the G3,
G4, G5, and G6 groups. The ureter was then sutured over
this catheter using 4/0 silk. Standard narrowing was thus
established in the ureters of the animals in these groups
undergoing partial obstruction. In groups G7, G8, G9, and
G10, undergoing complete obstruction, the left ureter was
tied off from two points with 4/0 silk. It was then severed,
and complete obstruction was thus established. Following
the surgical procedures, the abdominal incisions were
closed appropriately. The experimental groups are shown
in Table 1.

Table 1. Experimental study groups.
Group 1 (G1)

Sham, 1-week control (n = 6)

Group 2 (G2)

Sham, 3-week control (n = 6)

Group 3 (G3)

PUO, 1 week (n = 6)

Group 4 (G4)

PUO, 3 weeks (n = 6)

Group 5 (G5)

PUO + TMZ, 1 week (n = 8)

Group 6 (G6)

PUO + TMZ, 3 weeks (n = 8)

Group 7 (G7)

CUO, 1 week (n = 6)

Group 8 (G8)

CUO, 3 weeks (n = 6)

Group 9 (G9)

CUO + TMZ, 1 week (n = 8)

Group 10 (G10)

CUO + TMZ, 3 weeks (n = 8)

Experimental animals in groups G1, G3, G5, G7, and
G9 were sacrificed under general anesthesia (ketamine,
100 mg/kg, intraperitoneally) 1 week after obstruction, and
those in groups G2, G4, G6, G8, and G10 were sacrificed
under general anesthesia 3 weeks after obstruction. Blood
and tissue samples were collected. Blood specimens were
placed into gel-coated tubes, kept at room temperature
for 20–30 min, and then centrifuged for 15 min at
3000 × g. Serum specimens were kept as aliquots at
–80 °C. Left kidney tissues for use in the analysis were
obtained by total nephrectomy and stored at –80 °C.
2.2. Drug application
A single daily dose of TMZ (5 mg/kg) was administered by
intragastric lavage for 1 week after the surgical procedure
to the rats in groups G5 and G9 and for 3 weeks after the
surgical procedure to the rats in groups G6 and G10. A
minimum dose of 5 mg/kg was used in this study in order
to prevent rat losses, bearing in mind the expulsion of the
drug from the kidney.
All biological specimens in this study were obtained
at the Ondokuz Mayıs University Experimental Animals
Practice and Research Center, stored at –80 °C, and
transferred on dry ice and under appropriate conditions
to Ordu University once all groups had been established.
Specimens were kept in deep freeze at our faculty at
–80 °C until the day of the study.
Malondialdehyde (MDA) levels, myeloperoxidase
(MPO) activity, and CAT and GPx activity were measured
in tissue and serum specimens. As the increase of
creatinine and cystatin C measurements represents renal
insufficiency, creatinine and cystatin C measurements
were performed in serum specimens.
2.3. Creatinine measurement
This was performed in rat serum using commercial
creatinine kits (Creatinine Lot No: 78067UN14), on an
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Abbott Architect C8000 autoanalyzer, at the Ministry of
Health Ordu University Education and Research Hospital
biochemistry laboratory.
2.4. Cystatin C measurement
Cystatin C measurements in serum specimens were
performed using an ELISA kit specific to rats (Boster,
EK1109). Specimens were studied in 1:50 dilution, and
the results were read at 450 nm wavelength on an ELISA
reader (BioTek, Elx800).
2.5. MDA assay
A 2-thiobarbituric acid reactive substances (TBARS)
analysis kit (Cayman Cat No: 10009055, Lot No: 0459122)
was used for the measurement of MDA levels in tissue
and serum specimens. Tissues were washed in PBS
buffer (0.02 mol/L, pH 7.0–7.2) to remove all blood, and
homogenization was subsequently performed (100 mg
tissue/1 mL PBS). The tissue homogenates obtained were
subjected to freezing and thawing procedures, which were
repeated twice, and then centrifuged for 15 min at 1500 ×
g. The kit prospectus was applied to supernatants at a 1:10
dilution, and the results were read at 450 nm wavelength.
Results obtained for tissue were standardized with the
protein level (mg) in the homogenate.
2.6. MPO activity measurement
A rat-specific commercial ELISA kit (BlueGene: E02M0032,
Lot No: 20140825) was used for the measurement of MPO
in tissue and serum. Prior to homogenization, tissues
were washed in PBS buffer (0.02 mol/L, pH 7.0–7.2) for
blood removal. Homogenization was then performed (100
mg tissue/1 mL PBS). The tissue homogenates obtained
were twice frozen and thawed, and then centrifuged for
15 min at 1500 × g. Next, a 1:10 dilution was performed,
and the kit protocol was applied. The results were read at
450 nm wavelength. The results obtained for tissue were
standardized with the protein level (mg).
2.7. CAT activity measurement
A commercial CAYMAN analysis kit (Cayman Chemical
707002) was used in the measurement of CAT activity in
tissue and serum. Tissues were placed in homogenization
buffer (50 mM potassium phosphate, 1 mM EDTA, pH
7.0) (5 mL buffer/1 g tissue) and homogenized on ice, after
which they were centrifuged for 15 min at 10,000 × g. The
supernatants obtained were diluted 250-fold and used in
enzyme activity measurement. Results were read at 450
nm wavelength.
2.8. GPx activity measurement
Measurement of GPx in tissue specimens was performed
using spectrophotometry with a commercial Cayman
analysis kit (Cayman 703102). Prior to homogenization,
tissues were washed in PBS buffer (0.02 mol/L, pH 7.0–7.2)
for blood removal. Homogenization was then performed.
The tissue was washed in 5 mL of cold buffer (in 50 mM
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Tris-HCL, pH 7.5, 5 mM EDTA, and 1 mM DTT) per gram
of tissue and centrifuged for 15 min at 10,000 × g. GPx
measurement in serum specimens was performed using
a BlueGene commercial rat-specific ELISA kit (BlueGene
E02G0369).
2.9. Tissue protein measurement
Protein assay of tissue homogenates prepared as
described above was performed spectrophotometrically,
using the Bradford method (Thermo Scientific; 23200).
Measurements in specimens diluted at a level of 1:20 were
performed at 595 nm, and the protein level in the specimen
was determined on the basis of a standard chart.
2.10. Statistical analysis
Statistical analysis was performed using the one-way
ANOVA post hoc multiple comparisons Tukey test with
SPSS 16 software at a significance level of P < 0.05.
3. Results
Comparisons were performed in the 1- and 3-week groups
against the control groups. Group G1 was compared with
groups G3, G5, G7, and G9, while groups G2 and G4, G6,
G8, and G10 were compared among themselves. Values for
all parameters in the study are shown in Table 2.
3.1. Serum creatinine
Mean serum creatinine values for all groups are shown
in Table 2. Values were at the lowest level in the control
groups and increased in the study groups. Although a
statistically significant difference was observed between
G1 and G3 (P = 0.011), no significant differences were
determined among the other groups (P > 0.05) (Table 3).
No significant difference was observed between G2 and
the other 3-week groups (P > 0.05) (Table 4).
3.2. Serum cystatin C
Intergroup comparison revealed no statistically significant
difference between the 1-week groups (P > 0.05), while
in the 3-week groups significant differences were only
observed between G2 and G10 (P = 0.002) (Tables 3 and
4).
3.3. Serum and tissue MDA
No difference was observed among the 1-week groups
in terms of serum MDA levels (P > 0.05) (Table 3).
Comparison of the 3-week serum MDA levels revealed a
significant difference between G2 and G8 (P = 0.031), but
none among the other groups (P > 0.05) (Table 4). In terms
of tissue MDA levels, significant differences were only
determined between G1 and G3, G1 and G5, G1 and G7,
and G1 and G9 (P = 0.000; P = 0.000; P = 0.000; P = 0.002,
respectively) (Table 3). Comparison of the 3-week tissue
MDA groups and the control groups revealed a statistically
significant difference only between G2 and G6 (P = 0.047),
and none between the other groups (P > 0.05) (Table 4).
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Table 2. Mean values ± SEM for all the parameters in the experimental study.
S. creatinine
(mg/dL)

S. cystatin-C
(ng/mL)

S. MDA
(µmol TBARS)

T. MDA
(µmol TBARS/mg
protein)

S. MPO
(ng/dL)

T. MPO
(ng/mg protein)

S. CAT activity
(µmol/min/mg
protein)

T. CAT activity
(µmol/min/mg
protein)

S. GPx
(µmol/mL)

T. GPx activity
(ng/mL)

G1

0.437 ± 0.007

571.7 ± 19.61

25.78 ± 5.07

4.497 ± 0.309

45.73 ± 5.03

51.82 ± 7.51

0.360 ± 0.094

0.806 ± 0.136

135.5 ± 13.5

0.090 ± 0.020

G2

0.482 ± 0.008

572.4 ± 21.39

29.11 ± 5.83

3.763 ± 0.807

28.61 ± 4.41

45.66 ± 3.69

0.109 ± 0.017

0.636 ± 0.059

87.48 ± 17.35

0.086 ± 0.021

G3

0.530 ± 0.010

574.7 ± 14.98

35.47 ± 9.68

1.675 ± 0.491

22.51 ± 3.38

62.58 ± 6.33

0.120 ± 0.015

0.403 ± 0.025

95.69 ± 10.93

0.164 ± 0.011

G4

0.513 ± 0.026

557.9 ± 34.05

36.70 ± 3.71

2.390 ± 0.393

16.33 ± 0.72

41.38 ± 6.52

0.382 ± 0.148

0.957 ± 0.071

40.57 ± 9.62

0.090 ± 0.030

G5

0.501 ± 0.016

547.3 ± 47.01

60.59 ± 8.12

1.966 ± 0.424

19.18 ± 4.05

56.16 ± 4.81

0.166 ± 0.048

0.497 ± 0.026

47.37 ± 2.83

0.121 ± 0.018

G6

0.474 ± 0.014

607.8 ± 18.90

65.36 ± 9.46

2.067 ± 0.298

10.66 ± 1.38

61.96 ± 3.82

0.233 ± 0.065

0.805 ± 0.135

39.53 ± 3.44

0.213 ± 0.024

G7

0.508 ± 0.022

620.4 ± 11.04

75.28 ± 11.49

1.205 ± 0.085

20.01 ± 2.44

68.18 ± 2.99

0.357 ± 0.095

0.466 ± 0.032

78.15 ± 2.45

0.141 ± 0.027

G8

0.497 ± 0.018

612.8 ± 13.55

84.05 ± 16.42

2.045 ± 0.160

19.59 ± 2.79

66.57 ± 5.62

0.271 ± 0.084

0.406 ± 0.054

71.71 ± 2.45

0.151 ± 0.013

G9

0.506 ± 0.017

617.7 ± 46.39

76.33 ± 12.36

2.245 ± 0.154

14.66 ± 1.52

75.56 ± 3.63

0.585 ± 0.052

0.523 ± 0.022

55.58 ± 11.06

0.194 ± 0.020

G10

0.526 ± 0.015

819.4 ± 72.79

72.03 ± 12.96

2.533 ± 0.100

17.64 ± 2.96

77.08 ± 9.03

0.309 ± 0.062

0.459 ± 0.043

52.31 ± 8.18

0.148 ± 0.035

S: Serum; T: tissue; MDA: malondialdehyde; MPO: myeloperoxidase; GPx: glutathione peroxidase.

Table 3. Comparison of the 1-week groups.
S. creatinine
(mg/dL)

S. cystatin-C
(ng/mL)

S. MDA
(µmol TBARS/
mg protein)

T. MDA
(µmol TBARS/
mg protein)

S. MPO
(ng/dL)

T. MPO
(ng/mg
protein)

S. CAT activity
(µmol/min/mg
protein)

T. CAT activity
(µmol/min/mg
protein)

S. GPx
(µmol/mL)

T. GPx activity
(ng/mL)

G1–G3

0.011*

NS

NS

0.000*

0.000*

NS

NS

NS

NS

NS

G1–G5

NS

NS

NS

0.000*

0.000*

NS

NS

NS

0.000*

NS

G1–G7

NS

NS

NS

0.000*

0.000*

NS

NS

NS

0.028*

NS

G1–G9

NS

NS

NS

0.002*

0.000*

NS

NS

NS

0.000*

NS

*One-way ANOVA post hoc multiple comparisons Tukey test, P < 0.05; NS: nonsignificant, P > 0.05; S: serum; T: tissue; MDA: malondialdehyde; MPO: myeloperoxidase; GPx: glutathione peroxidase.

Table 4. Comparison of the 3-week groups.
S. creatinine
(mg/dL)

S. cystatin-C
(ng/mL)

S. MDA
(µmol TBARS/
mg protein)

T. MDA
(µmol TBARS/
mg protein)

S. MPO
(ng/dL)

T. MPO
(ng/mg protein)

S. CAT activity
(µmol/min/mg
protein)

T. CAT activity
(µmol/min/mg
protein)

S. GPx
(µmol/mL)

T. GPx activity
(ng/mL)

G2–G4

NS

NS

NS

NS

NS

NS

NS

NS

NS

NS

G2–G6

NS

NS

NS

0.047*

0.004*

NS

NS

NS

NS

0.012*

G2–G8

NS

NS

0.031*

NS

NS

NS

NS

NS

NS

NS

G2–G10

NS

0.002*

NS

NS

NS

0.010*

NS

NS

NS

NS

*One-way ANOVA post hoc multiple comparisons Tukey test, P < 0.05; NS: nonsignificant, P > 0.05, S: serum, T: tissue, MDA: malondialdehyde, MPO: myeloperoxidase, GPx: glutathione peroxidase.

3.4. Serum and tissue MPO
Comparison of the 1-week groups in terms of serum MPO
values revealed significant differences between G1 and G3,
G1 and G5, G1 and G7, and G1 and G9 (P = 0.000; P =

0.000; P = 0.000; P = 0.000, respectively). There was no
difference between the 1-week groups in terms of tissue
MPO levels (P > 0.05) (Table 3). Comparison of the 3-week
groups revealed statistical significance only between G2
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and G6 (P = 0.004), and none between the other groups
(P > 0.05). In the tissue MPO levels, the only significant
differences in the 3-week groups were between G2 and
G10 (P = 0.01) (Table 4).
3.5. Serum and tissue CAT activity
Comparison of both 1- and 3-week serum CAT activities
revealed statistically insignificant differences between
groups (P > 0.05) (Table 3). Tissue CAT activities were
only significantly different between G1 and G3 (P = 0.019).
In the 3-week groups, no significant differences were
determined between the other groups (P > 0.05) (Table 4).
3.6. Serum GPx levels and tissue GPx activity
Serum GPx levels were only significantly different in the
1-week groups between G1 and G5, G1 and G7, and G1 and
G9 (P = 0.000; P = 0.028; P = 0.000, respectively), while no
significance was determined among the 3-week groups (P
> 0.05). Analysis of tissue GPx activities among the groups
revealed no significance between the 1-week groups (P >
0.05), but significant differences were determined between
G2 and G6 (P = 0.012) in the 3-week groups (Tables 3 and
4).
4. Discussion
Ureteral obstruction in clinical practice may be partial
(PUO) or complete (CUO). The severity of the obstruction
and the damage it causes depend on its duration, form,
and location. Reflections of severity of injury in the
obstructed kidney also vary, depending on whether or not
the contralateral kidney is normal (1).
In UUOs, cellular and molecular mechanisms in
the ipsilateral kidney are affected. This leads to varying
degrees of inflammation, apoptosis, increased oxidative
stress, fibrosis, and kidney loss, depending on whether the
obstruction is partial or complete. These processes take
place in a shorter time when the obstruction is complete
(7–9).
Large numbers of locally produced cytokines, various
growth factors, ROS, and reactive nitrogen species are
involved in the pathogenesis of UUO. In addition, it has
been shown that an increase in reactive products may
give rise to DNA injury during and as a result of lipid
and protein oxidation in ureteral obstruction. Injury may
also be greater with a decrease in antioxidant enzyme
activities due to a reduction in antioxidant products and
increased oxidant products in the cells in association with
obstruction (2,7–9).
Clinical and experimental studies have been performed
on the subject of UUOs, and many substances have been
investigated in both tissue and serum (13–15). This is the
first study on the effect of TMZ on ureteral obstruction and
5 mg/kg daily is a minimum dose. Ureteral obstructions
generally need to be treated, and the obstruction should
be removed within 3 weeks (1). Research is still taking
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place to determine the effects of medication therapies to
reduce kidney damage to a minimum during obstruction,
until the blockage is removed by surgery or some other
form of treatment. In this study, we used TMZ, an
antiischemic drug widely used in daily practice and with
a marked protective effect on the heart. Trimetazidine
has been shown to be an antianginal and antiischemic
agent, to improve myocardial energy metabolism, to
activate glucose oxidation, to have antioxidant properties,
to suppress apoptosis, to increase nitric oxide (NO), to
protect intracellular adenosine triphosphate levels, and
to prevent intracellular acidosis and inorganic phosphate
deposition (10,16–18). Trimetazidine causes a significant
increase in SOD and CAT and a significant decrease in
MDA and MPO levels in Sprague Dawley rats (16–18).
In our study, 1-week rat groups were established to
investigate the short-term results after PUO and CUO,
and 3-week groups were formed to investigate the longterm results. MDA, MPO, CAT, and GPx were investigated
in serum and in tissue to show increases in oxidative
stress, whether that stress would decrease, and whether
antioxidant capacity would increase in the drug groups.
In addition, serum creatinine and cystatin C levels were
investigated in all groups. Increases were observed in
serum creatinine and cystatin C levels in all groups using
TMZ. Maximum serum creatinine and cystatin C levels
were observed in 3-week CUO. Serum creatinine values
decreased in 1-week and 3-week PUO with TMZ, but it
increased in all the CUO + TMZ groups. Cystatin C levels
were largely similar to creatinine. This shows that TMZ
compromises kidney function in both the long and the
short term in partial obstructions. In complete obstruction,
TMZ significantly impairs kidney functions. Indeed, TMZ
is eliminated from the body through the kidneys (20). An
antioxidant, antiischemic agent eliminated from the body
through the kidneys might be expected to have a better
healing effect in kidney tissues and to act as a corrective
factor. However, this was not observed in our study. To our
knowledge, there are no data about the nephrotoxicity of
TMZ in the literature.
The oxidative damage markers of serum and tissue
MDA and MPO, serum GPx levels, tissue GPx activity,
and serum and tissue CAT activity were investigated in
this study.
Free oxygen radicals play important roles in the
pathophysiology of ureteral obstruction. Accumulation of
MDA in serum and tissue occurs as a result of oxidative lipid
peroxidation (19). MDA is formed from polyunsaturated
fatty acids. Its major precursors are generally regarded as
arachidonic acid and docosahexaenoic acid (20). MDA
reacts with nucleic acid bases in DNA and ribonucleic
acid, similarly to those in proteins, to form various
products (19). Although studies have reported that TMZ
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reduces MDA levels in ischemia-reperfusion injury (16),
no difference was observed in serum MDA levels in the
1-week groups in our study. Serum MDA levels were
highest in the 3-week CUO group. A slight increase
occurred in the partial obstruction groups. MDA levels
continued to increase in the 1- and 3-week complete and
partial obstruction groups that were administered TMZ. In
terms of tissue MDA levels, change was either minimal or
nonexistent in the groups receiving the drug compared to
the partial and complete obstruction groups not receiving
the drug.
Similarly to our own study, Tirani et al. reported
a significant increase in tissue MDA levels after 24 h in
rats with bilateral induced ureteral obstruction (21).
While increases were observed in our study in terms of
serum MDA levels compared to the sham group, the exact
opposite was observed in tissue MDA. This may be due
to the contralateral kidney contributing to MDA values
as a result of obstruction being induced unilaterally. In
addition, the decrease in tissue MDA shows that lipid
peroxidation does not occur in obstructed kidneys,
in a manner incompatible with findings in ischemiareperfusion injury. Further varied and detailed studies are
needed on this subject.
Analysis of serum and tissue MPO levels in this
study revealed a decrease in serum levels and an increase
in tissue levels. MPO is a proinflammatory enzyme
stored in the azurophilic granules of neutrophils (22).
It catalyzes the formation of hypochlorous acid from
hydrogen peroxide. Gene polymorphism has been
reported (23,24). Enzymatic activity can vary significantly
between individuals. Increases and decreases in activity
have therefore both been reported (23,24). A significant
difference was observed in our study in terms of serum
values between the sham group and the other groups.
Serum MPO values decreased in CUO and PUO and in the
drug groups, while tissue MPO levels increased. Similar
findings were observed in the 3-week group. While TMZ
increased antioxidant activity in renal tissue, serum MPO
levels decreased. However, in a study of thermal injuryrelated intestinal mucosa and kidney damage, Yalçın et al.
(18) reported that TMZ reduced MDA levels in cardiac
ischemia-reperfusion injury (16). They also observed, in
contrast to our study, that it reduced intestinal MPO levels.
CAT converts hydrogen peroxide into water and
molecular oxygen. The cells are thus protected against

damage by hydrogen peroxide. In addition, alcohols such
as methanol and ethanol oxidize into formaldehyde and
acetaldehyde under the effect of peroxidase in the presence
of hydrogen peroxide (5). Serum CAT activities increased
in our CUO + TMZ groups (1 week and 3 weeks, G9 and
G10) compared to the CUO groups without TMZ. The
same increases also occurred in renal tissue CAT activities
in the same groups. Tissue CAT activities increased
with length of partial obstruction. The effect of TMZ on
tissue CAT activity in the partial obstruction groups was
slight. GPx represents a broad enzyme family that uses
glutathione. They reduce hydrogen peroxide or organic
hydroperoxides to water or alcohol, respectively. The GPx
family metabolizes lipid hydroperoxides, but CAT serves
no such function. Therefore, the absence of an increase in
CAT activity despite a rise in GPx activity shows that lipid
hydroperoxides are implicated in oxidative stress response
in ureteral obstruction (14). Serum GPx levels and tissue
GPx activity were also measured in this study. Serum
GPx levels decreased in both the 1- and 3-week CUO
groups receiving TMZ. The same decrease occurred in the
1-week PUO group receiving TMZ, but it was minimal in
the 3-week TMZ group. Tissue GPx activity rose to the
highest level in the 3-week PUO + TMZ group. Tissue GPx
activity increased in almost all groups compared to the
sham groups. Kinter et al. showed that increased sodium
wasting in rats in which they induced unilateral CUO did
not change antioxidant enzyme CAT levels but did cause a
slight increase in GPx (14).
No renal oxidative stress-lowering effect was observed
in UUO in rats when TMZ was used at a dose of 5 mg/
kg daily. Additionally, it had a minimal adverse effect
on renal function. New studies are planned for different
doses. Future studies involving oxidant and antioxidant
systems in both the ipsilateral and contralateral kidneys in
UUO may provide more detailed information concerning
serum values. Patients using TMZ, an antiischemic and
antioxidant agent, must be closely monitored in terms
of kidney function. The possibility that the drug may
compromise kidney functions should be considered and
appropriate measures should be taken.
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